Melin, P. et al. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur. J. Gastroenterol. Hepatol. 22, 1050-1057

Department of Polyvalent Medicine, Hospital of Saint Dizier, Saint-Dizier, France.
European journal of gastroenterology & hepatology (Impact Factor: 2.25). 03/2010; 22(9):1050-7. DOI: 10.1097/MEG.0b013e328338d9aa
Source: PubMed


Injection drug users are often excluded from hepatitis C virus (HCV) treatment. This study compares sustained virological response, adherence, and quality of life in patients with or without a history of illicit drug use in routine clinical practice.
This is a post-hoc analysis of a prospective, observational study conducted in 1860 patients who received peginterferon alpha-2b/ribavirin combination therapy. Nondrug users (NDUs) were defined as patients without a history of drug addiction; former drug users (FDUs) as patients who had stopped using illicit drugs or opioid maintenance therapy and active drug users (ADUs) as patients using illicit drugs or on opioid maintenance therapy. Virological response, adherence, and the health-related quality of life were assessed by the measure of HCV RNA in the serum, self-report and 36-item short-form health survey Questionnaire, respectively.
The analyzed population included 1038 (56%) NDUs, 578 (31%) FDUs, and 244 (13%) ADUs. About 85% of ADUs were on opioid maintenance therapy and 25% used illicit drugs. Although ADUs had a more chaotic lifestyle and more psychiatric disorders, sustained virological response of ADUs (58%) did not differ from that of NDUs (49%) and FDUs (51%) (P=0.133). Adherence rates were 39% in NDUs and FDUs, and 37% in ADUs (P=0.883). Health-related quality of life was improved in the three groups after the end of treatment.
Our study suggests that HCV therapy in ADUs on opioid maintenance therapy is as effective as in other HCV patients. The effectiveness of HCV therapy in illicit drug users needs to be evaluated in further studies.

25 Reads
  • Source
    • "Sustained virologic response rates in PWID/noninjecting drug users were around 40% and did not differ significantly after adjustment for HCV genotype.75 Likewise, a French cohort study demonstrated a similar sustained virologic response in active drug users and patients on opioid substitution treatment (58%) as compared with former (51%) and nondrug users (49%), despite a more chaotic lifestyle and higher rate of psychiatric comorbidity.76 Moreover, in a prospective study comparing sustained virologic response rates in four groups (patients without a history of psychiatric disorders or drug abuse, psychiatric patients, opioid-substituted patients, former drug users), an overall sustained virologic response rate of 58.6% was found. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis C virus (HCV) infections are highly prevalent amongst people who inject drugs (PWID). Despite well documented evidence of its effectiveness, suggested cost-effectiveness, and potential to reduce HCV prevalence rates, the uptake of antiviral HCV treatment by PWID is low. This nonsystematic literature review describes factors associated with the uptake, adherence, and efficacy of HCV treatment among PWID and discusses strategies to increase their uptake of treatment. Low HCV treatment uptake among PWID is associated with a number of patient-related and provider-related barriers. Beliefs and fears about low efficacy and adverse effects on the patient's part are common. A substantial number of factors are associated with the chaotic lifestyle and altered social functioning of PWID, which are often associated with decompensation or relapsing into drug addiction. This may lead to perceived low adherence with treatment and low efficacy on the provider's part too, where lack of support, inadequate management of addiction, and other drug-related problems and poor treatment of side effects have been described. Practical issues such as the accessibility of treatment and finances also play a role. Strategies to improve the HCV treatment rate among PWID involve pretreatment management and assessment, a multidisciplinary approach, management of side effects, and enhanced education and counseling. Specific factors are associated with poorer treatment outcomes in PWID on the side of both the patient and the treatment system. However, given that PWID can achieve treatment adherence and sustained virologic response rates comparable with those in nondrug users, drug use per se should not be considered a criterion for exclusion from treatment. Further development of measures leading to higher uptake of treatment and adherence in PWID and appropriate adaptation of HCV treatment guidelines represent important tools in this regard.
    Full-text · Article · Oct 2013 · Patient Preference and Adherence
  • Source
    • "In parallel with the need to design HCV treatment as part of a combination intervention approach, it appears that optimal conditions for treatment delivery comprise integrating care through multidisciplinary teams [14,57,61,123,124]. The delivery of HCV treatment in drug and alcohol settings is an effective way of facilitating low threshold access to HCV treatment as well as integrating treatment alongside other forms of health and social care [15,50,60,61,117]. Yet recent research also cautions against simply ‘adding on’ HCV treatment to drug and alcohol services that are ill equipped to offer flexible and multi-disciplinary care [132,133]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Evidence documents successful hepatitis C virus (HCV) treatment outcomes for people who inject drugs (PWID) and interest in HCV treatment among this population. Maximising HCV treatment for PWID can be an effective HCV preventative measure. Yet HCV treatment among PWID remains suboptimal. This review seeks to map social factors mediating HCV treatment access. Method We undertook a review of the social science and public health literature pertaining to HCV treatment for PWID, with a focus on barriers to treatment access, uptake and completion. Medline and Scopus databases were searched, supplemented by manual and grey literature searches. A two step search was taken, with the first step pertaining to literature on HCV treatment for PWID and the second focusing on social structural factors. In total, 596 references were screened, with 165 articles and reports selected to inform the review. Results Clinical and individual level barriers to HCV treatment among PWID are well evidenced. These include patient and provider concerns regarding co-morbidities, adherence, and side effect management. Social factors affecting treatment access are less well evidenced. In attempting to map these, key barriers fall into the following domains: social stigma, housing, criminalisation, health care systems, and gender. Key facilitating factors to treatment access include: combination intervention approaches encompassing social as well as biomedical interventions, low threshold access to opiate substitution therapy, and integrated delivery of multidisciplinary care. Conclusion Combination intervention approaches need to encompass social interventions in relation to housing, stigma reduction and systemic changes in policy and health care delivery. Future research needs to better delineate social factors affecting treatment access.
    Full-text · Article · May 2013 · Harm Reduction Journal
  • Source
    • "In addition, the treated patients had favorable features for achieving SVR (e.g., predominantly Caucasian with a high prevalence of HCV genotypes 2 or 3) [9] [10] [11] [12] [13]. On the other hand, studies of drug users and racial and ethnic minorities have shown substantially lower SVR rates in clinical practice settings [14] [15]. No study has examined the overall effectiveness of care among all patients presenting with chronic HCV in a national healthcare system, while examining various steps in clinical care such as HCV genotype testing; contraindications to treatment; initiation of treatment; completion rates; and SVR. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Antiviral treatment for hepatitis C virus (HCV) has high efficacy rates for achieving sustained viral response (SVR) in randomized controlled trials (RCTs) (40-80%); however, it can be lower in community-based practice settings. We wanted to determine the effectiveness of HCV treatment in Veterans Administration (VA) hospitals nationwide. Using the nationwide VA HCV Clinical Case Registry (CCR), we examined a cohort of veterans who had HCV viremia between 2000 and 2005 and identified patients who received pegylated-interferon (PEG-INF) and ribavirin. The duration of treatment and proportion of patients completing treatment was calculated. The effectiveness of treatment was measured as the proportion of patients who achieved SVR (negative viremia at least 12 weeks after the end of treatment) in the entire cohort, and among patients who initiated and completed treatment. We identified 99,166 patients with HCV viremia. Of those, 11.6% received PEG-INF with ribavirin and 6.4% completed treatment. Contraindications were present in 57.2% of the patients that did not receive treatment. SVR was documented in 39.9% and 58.3% of patients who completed treatment; 23.6% and 50.6% of patients who initiated treatment; and 3.9% and 11.2% of the entire HCV cohort for genotype 1 or 4 and 2 or 3, respectively. Overall, only 3.5% of the entire HCV viremic cohort had a documented SVR. Treatment effectiveness for HCV is low. In addition to fixed factors, such as race and virus genotype, the drop in effectiveness is due to low rates of antiviral treatment initiation and treatment completion.
    Preview · Article · Jul 2011 · Journal of Hepatology
Show more